Introduction
The production of new blood vessels (BVs) occurs through one of two main mechanisms: angiogenesis that refers to the formation of new BVs from pre-existing BVs 1 and vasculogenesis that refers to the formation of new BVs by the in situ differentiation from pre-existing precursors. 2 These precursors are either present locally or mobilize from another site -such as bone marrow -to participate in the production of the new BVs. 3 In vitro studies have shown that populations derived from marrow stroma are pluripotent and have the ability to differentiate into several cell types including osteoblasts, chondroblasts, fibroblasts, adipocytes, skeletal myoblasts, cardiomyocytes, and endothelial cells. [4] [5] [6] [7] [8] In addition to their stem-cell-like ability, marrow stromal cells (MSCs) are abundant in all age groups, easy to harvest, culture and expand in vitro making them a desirable cell type for autologous regenerative cell therapy. 9 In this study, we explored the utilization of MSCs for the in vivo production of new BVs in normal mice. We assessed the MSCs' ability to stimulate angiogenesis and arteriogenesis, and to differentiate into endothelial cells participating in the newly formed vascular structures. We demonstrate that MSCs possess functional vascular plasticity and elicit a robust hostderived angiogenic response.
Methods

Harvest and culture expansion of murine MSCs
Female C57Bl/6 mice (18-20 g) were obtained from Charles River Laboratories (Laprairie Co. , Quebec, Canada), and these isogenic mice were used as donors and recipients of MSCs to simulate autologous implantation. Mice were killed by CO 2 inhalation and bone marrow cells harvested by flushing femurs and tibias with DMEM supplemented with 10% FBS and 50 U/ml penicillin/streptomycin. Whole marrow was plated in tissue culture dishes, and 5-7 days later the nonadherent hematopoietic cells were discarded. The adherent bone MSCs were maintained in a humidified incubator at 371C with 5% CO 2 in the absence of any exogenous growth factor or anchoring materials such as fibronectin or collagen. MSCs were kept subconfluent and expanded in number over 14 passages by a 1:2 split on a weekly basis.
Generation of LacZ gene-modified MSCs
In gene marking studies, MSCs were stably transduced with integrating retroviral vectors as previously described. 10 Retrovectors encoding green fluorescent protein and the human drug resistance gene cytidine deaminase 11 as well as LacZ 12 were utilized to generate a polyclonal population of gene-marked MSCs. Following LacZ transduction, 70-95% of all gene-modified MSCs expressed detectable b-galactosidase activity as assessed by X-gal staining. These LacZ + MSCs were expanded in number for an additional month before implantation in isogenic C57Bl/6 mice. We were able to monitor and identify the implanted LacZ + MSCs and their progeny with histochemistry by a characteristic indigo-blue (in H&E-stained sections) or green-blue color (in sections stained with DAB) when incubated with X-gal solution.
Murine Matrigel assay
Matrigelt (Becton Dickinson, Mississauga, Ontario, Canada) was used as a three-dimensional in vivo model of angiogenesis. 13 On the day of implantation, MSCs were trypsinized. These cells or recombinant factors were resuspended in cold Matrigel, and 0.5 ml was injected subcutaneously in the right flank in each test mouse. At 14 or 28 days postimplantation, we killed the mice and flushed the systemic circulation through the left ventricle with 15 ml of cold (41C) phosphate-buffered solution (PBS), followed by 15 ml of cold 2% paraformaldehyde (PFA). Matrigel implants were dissected and placed in 2% PFA at 41C for 24 h followed by incubation in X-gal staining solution, which consisted of 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 Á 3H 2 O, 0.01% sodium deoxycholate, 2 mM MgCl 2 , 1 mM EGTA, and 1 mg/ml X-gal made in wash solution (PBS with 0.02% NP40). After 16 h, specimens were fixed in 10% formalin, embedded in paraffin and sections cut at 3-4 mm intervals.
Immunohistochemistry
Deparaffinized sections were blocked with serum and incubated at 371C with primary antibodies polyclonal goat anti-mouse CD31 (1:100), or polyclonal rabbit anti-VEGF (1 : 100), which recognizes the 165, 189, and 121 splice variants of VEGF (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by biotinconjugated secondary antibodies: 1:100 donkey anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or 1:200 goat anti-rabbit (BD Pharmingen, San Diego, CA, USA). Sections were washed and then treated with avidin-peroxidase (ABC Elite kit, Vector Laboratories, Burlington, Ontario, Canada) for 30 min. The reaction was developed with DAB substrate (Vector Laboratories); sections were counterstained with hematoxylin. Modified Masson's trichrome staining was performed as described by Brown. 14 
Flow cytometry
Culture-expanded MSCs were trypsinized and subsequently stained with the following monoclonal antibodies (Abs): phycoerythrin (PE)-labeled anti-CD44 (clone IM7), anti-CD45 (clone 30-F11), anti-Flk1 (clone Avas12a1), biotinylated anti-CD31 (clone 390), anti-CD34 (clone RAM34), all from BD Biosciences (San Diego, CA, USA), and biotinylated anti-Flt4 (clone AFL4), anti-Tie2 (clone Tek 4) from ebioscience (San Diego, CA, USA). Biotinylated Abs were revealed by CyChrome streptavidin (BD Biosciences). PE-labeled or biotinylated rat isotypic control immunoglobulins were from BD Biosciences. Events were acquired on a Coulter EPICS flow cytometer (Beckman Coulter, Fullerton, CA, USA) and analyzed by means of Win MDI 2.7 software.
In vitro differentiation of MSCs and capillary tube assay
Two 30 mm tissue culture plates were coated with Matrigel according to the manufacturer's instructions. MSCs were seeded on the Matrigel at 2 Â 10 4 cells per plate in DMEM with 10% FBS and incubated at 371C with 5% CO 2 . In one of the two plates, we added murine VEGF 165 at 50 ng/ml concentration. In parallel experiments, MSCs were cultured over cover slips in the same medium described above with and without murine VEGF 50 ng/ml for 14 days. Immunofluorescence staining was performed on coverslip adherent cells after fixation in ice-cold methanol for 20 min followed by serum blocking in 5% BSA and 5% donkey serum in PBS for 30 min. Cells were incubated with goat anti-mouse CD31 for 1 h at room temperature and then incubated with donkey anti-goat IgG antibody for 30 min at room temperature, followed with 1 : 500 streptavidin-Texas red for 30 min. Cells were washed several times with PBS after each step. Cover slips were mounted on slides with Gelvatol.
Microscopy and vascular density
All sections were examined with an Olympus BX60 microscope. Digital images were analyzed with Image Pro software (Media Cybernetics). In H&E-stained sections, we considered as BVs only tubular structures within the Matrigel that were lined with endothelium and had a patent lumen. In sections stained with anti-CD31 antibody/peroxidase, we considered as BVs only tubular structures within the Matrigel that were CD31 + (ie peroxidase positive). For vascular density measurements, we measured the surface area of each section (excluding the capsule) using Â 400 magnification and Image Pro software, and CD31 + (ie peroxidase positive) tubular cross-sections were deemed representing a blood vessel and enumerated. Vascular density was expressed as BVs/mm 2 . Diameter of BVs was measured using the same software.
Statistical analysis
All data are expressed as the mean7s.d. Statistical analysis was carried out using the SPSS version 10.0 (SPSS Inc.).
Results
Phenotypic analysis of MSCs
In vitro culture-expanded adherent MSCs were uniformly fibroblast-like in appearance. Analysis by flow cytometry performed at passage 14 revealed that MSCs expressed CD44 and CD34, yet were negative for CD45, CD31, flk1/kdr (VEGF-R2), flt-4 (VEGF-R3), and Tie2 (angiopoietin receptor) ( Figure 1 ). We did not detect expression of VEGF by immunohistochemical analysis of these cells (data not shown). Progeny derived from this population was utilized for all subsequent in vivo analysis.
MSCs stimulate angiogenesis
At 2 weeks after in vivo subcutaneous implantation with Matrigel, large macroscopic BVs grew into Matrigel plugs containing MSCs, while negative control plain Matrigel was avascular. We noticed the growth of small 2 for the VEGF, bFGF, and negative control groups, respectively (Po0.001) ( Figure 4 ). When we assessed the angiogenic response at 28 days, the macroscopic and microscopic differences between the groups were even more evident (Figure 3a -l). The MVD in Matrigel plugs containing 2.0 Â 10 6 MSCs/ml at 28 days was 7879 BV/mm 2 compared to 1174, 770.8, and 270.5 BV/mm 2 for the VEGF, bFGF, and negative control groups, respectively (Po0.001). Comparing results at 14 and 28 days using 2.0 Â 10 6 MSCs/ml showed a 100% increase in the MVD (Po0.001). In contrast, implants containing VEGF 165 and bFGF showed a reduction of the MVD assessed at 28 days in comparison with 14 days measurements (P¼0.01 for VEGF 165 and P¼0.037 for bFGF). We compared the vascular densities associated with different numbers of MSCs (range 1-8 Â 10
6 MSCs/ml) at 14 days (Figure 4) . Results demonstrate the presence of a dose-response relationship between the number of MSCs per milliliter and the density of BVs. The differences were statistically significant up to 4.0 Â 10 6 MSCs/ml (Po0.001).
MSCs stimulate arteriogenesis
In random sections of the Matrigel specimens, we assessed development of arterioles defined by their size (BVsX20 mm in diameter) and their structure (BVs containing smooth muscle in their wall). Using Masson's trichrome staining, we observed smooth muscle bundles in the wall of several BVs per section in the MSCMatrigel plugs (Figure 5a and b) . None of the sections obtained from VEGF, bFGF, or negative control groups contained BVs with smooth muscle in their wall (data not shown). The density of BVsX20 mm was significantly increased at 14 days in all MSC groups when compared (Figure 6j ). These findings are consistent with in vivo phenotypic differentiation of MSCs into endothelium. We also observed LacZ + MSCs in the subendothelial layer, where they were elongated and aligned circumferentially in the wall of BVs ( Figure   6i ). This was a frequent observation in the wall of large BVs. We speculate that these MSCs differentiated into vascular smooth muscle, a phenomenon which has been shown before in vitro with MSCs. 15, 16 Based on LacZ gene reporter activity, we found that implanted LacZ Figure  2l) . We also observed a mild to moderate neutrophilic infiltrate associated with MSCs, recombinant VEGF, and bFGF, but not with empty Matrigel (data not shown).
The role of VEGF
De novo production of VEGF in vivo might be one of the means by which MSCs induce a host-derived angiogenic response. To test this hypothesis, we used neutralizing antimurine VEGF antibodies that were mixed with the MSCs in the Matrigel plugs prior to implantation. At 2 weeks after implantation, there was no visible BVs macroscopically and there was a markedly reduced angiogenic response in histological sections. However, viable LacZ + MSCs were present (Figure 7a and b) . The 
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visible organized vascular network in Matrigel implants containing MSCs (d and h). H&E-stained sections: (i) plain Matrigel implant (magnification, Â 100). (j) Matrigel containing bFGF shows fibrosis (arrow heads) (magnification, Â 100). (k) Matrigel containing VEGF 165 shows multiple thin-walled, dilated vascular channels (arrows), (Magnification, Â 200). (l) Matrigel implant containing MSCs shows moderate cellularity with numerous capillaries and branching vessels (arrowheads) (magnification, Â 200). Histological analysis of specimens shown is representative of findings observed in four Matrigel-implanted animals per test group.
Figure 4 MVD measured at 14 and 28 days after implantation of MSC-bearing Matrigel. Blood vessels were enumerated as detailed in the Materials and methods section. MSCs were embedded in Matrigel in concentrations ranging from 1 to 8 Â 10 6 cells/ml. In comparison, we mixed either 25 ng of murine VEGF165 or 500 ng of bovine bFGF with 0.5 ml of Matrigel per implant, which were examined at 14 and 28 days postimplantation. As a negative control, we used 0.5 ml of plain Matrigel mixed with 50 ml of RPMI medium. The average of four independent matrigel implants per test group was analyzed at all time points (average7s.d. is shown), and experiments involving MSCs were repeated twice with two independent sets of MSCs. 
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Discussion
MSCs can be used for cell therapy, and have been studied in early phase clinical trials in autologous 17 and allogeneic 18 settings. In preclinical studies, isogenic MSCs have been explored as stem cells for tissue regeneration, and they were able to engraft and differentiate in tissues such as the brain 19 and myocardium. 20 In this study, we have demonstrated the spontaneous angiogenic and vasculogenic activities of culture-expanded MSCs using an in vivo murine Matrigel model, and have examined the interplay of MSCs, de novo VEGF production in vivo, and host angiogenic response.
We have found that ex vivo culture-expanded marrowderived stromal cells in the absence of growth factors express CD44, a marker consistent with MSCs 9 yet distinct from marrow-derived multipotent adult progenitor cells (MAPCs). 21 Hematopoietic cells were absent with less than 1% CD45 + cells in our system. Further, our MSCs do not express CD31, consistent with what was previously described by others. 4, 9 We also determined that they do not express VEGF, kdr/flk1 (VEGF-R2), and Tie2 in vitro (Figure 1) , and the sum of these phenotypic characteristics distinguishes them from mature endothelial cells, as well as endothelial progenitor cells, 3, 22, 23 endothelial precursor cells 24 or angioblasts. 25 Similarly, MSCs cultured ex vivo in Matrigel do not adopt CD31 + / VEGF + endothelial phenotype spontaneously, although a subset could undergo endothelial transdifferentiation following addition of recombinant VEGF 165, suggesting that Matrigel-embedded MSCs are poised for VEGF responsiveness (Figure 7) . Intriguingly, we found that our anchorage-dependent cells expressed CD34 robustly in the absence of either endothelial (CD31, kdr) or hematopoietic (CD45) markers. The significance of this observation is unclear, and may reflect the plasticity reported with pluripotent MSCs, where contemporaneous expression of multiple lineage markers may occur. 26, 27 We show that Matrigel-embedded MSCs implanted subcutaneously elicit a robust angiogenic response at 2 and 4 weeks (Figures 2 and 3 ), leading to a significant increase in vessel density (Figure 4) . Further, MSCs + and VEGF + spontaneously in vivo without the need of exogenous angiogenic factors ( Figure 6 ). The in vivo vascular differentiation of MSCs may be explained by several mechanisms including 'contact-signaling', in which the direct interaction between the MSCs and Matrigel and/ or host-derived cells initiates vascular differentiation. Matrigel is derived from a murine sarcoma cell line and contains a wide array of 'basement membrane' components, any of which may provide signals promoting endothelial differentiation. Although Matrigel supports the endothelial differentiation of MSCs in vivo, alternative and distinct phenotypes may arise depending upon the type of proteinaceous matrix scaffolding provided. 28 These results are complementary to the previous report by Reyes et al. where MAPCs -an anchorage-dependent cell type copurified with MSCsexpress VEGF receptors and can adopt an endothelial phenotype in vitro following exposure to VEGF, 4 and can participate in wound and tumor neoangiogenesis. 28 We make the comparison cautiously since MAPCs are obtained by culture of lineage-depleted marrow on fibronectin-coated plates in the presence of EGF, PDGF, ascorbic acid, dexamethasone, and low serum -a procedure distinct from our MSC, Friedenstein-like 29 culture system also used by others in the field. 5, 30 Hence is our uncertainty about comparability of populations reported by Reyes et al and here studied.
As part of our analytic approach, we utilized retroviral gene marking of MSCs with LacZ to distinguish MSC contribution to the angiogenic response from the recruitment of endogenous 'host' vascular structures. We have observed that more than 99% of the neovascular response is host-derived, reflecting the extraordinarily potent recruitment effect MSCs possess -above and beyond their direct contribution to new vessel formation via transdifferentiation. Indeed, this observation leads us to speculate that 'small, logistically feasible' cellular implants may lead to significant pharmacological effects -That is, therapeutic neovascularization. We have also noted an increase in MVD over time -from 2 to 4 weeks -in Matrigel plugs embedded with MSCs; whereas, in the Matrigel plugs embedded solely with recombinant VEGF (or bFGF), a decline in MVD was observed in the same time period. Taking into account the finite half-life of recombinant proteins and the inevitable decline of pharmacological effect over time, it suggests that continuous production of factors by MSCs is required for a sustained and robust neovascularization effect.
We found that Matrigel-embedded stroma did not spontaneously differentiate in vascular tubes in tissue culture in vitro unless we added recombinant VEGF to the system. Therefore, Matrigel in itself is insufficient to promote vasculogenesis de novo in the absence of a supplementary stimuli occurring in vivo. Although serum from animals with an acute myocardial infarct will stimulate proliferation of endothelial precursors, 25 our experimental model was devoid of ischemic organ injury and a serum-bound MSC transdifferentiation factor is unlikely. Since the VEGF gene is hypoxiaresponsive, 31 and we demonstrated de novo VEGF production by MSCs in vivo, we speculate that reduced oxygen tension milieu of Matrigel implant may provide the stimulus required to promote VEGF production by MSCs. We propose that VEGF production by MSCs occurs as part of an adaptive response to the relative hypoxia of the Matrigel milieu in vivo. Autocrine and/or paracrine effects of locally produced VEGF lead to MSC vasculogenic response and simultaneously initiate a potent host-derived angiogenic response. Although neutralizing anti-VEGF antibodies almost completely abolished both vasculogenesis and angiogenesis, it would seem that VEGF protein on its own is insufficient to mediate a balanced angiogenic response, since we found that Matrigel plugs embedded solely with recombinant VEGF (or bFGF) led to histologically abnormal angiogenesis, akin to what has been observed by others. [32] [33] [34] . Arteriogenesis is an essential feature of normal vascularization. We observed the development of arterioles only in Matrigel plugs incorporating MSCs. In contrast, there was virtually no arteriogenesis observed in Matrigel plugs embedded with recombinant VEGF or bFGF. Although we speculate that MSCs may differentiate into smooth muscle cells and participate in arteriogenesis, it is likely that the bulk of arteriogenesis is host-derived. The sum of these observations leads us to speculate that MSC-bound or secreted factors (distinct from bFGF or VEGF) are likely involved in the observed balanced angiogenic and arteriogenic response.
In sum, we have found that implanted MSCs adopt histological and immunophenotypic characteristics consistent with endothelial cells functionally related to vascular structures. Although vasculogenesis arising from transdifferentiation of MSCs occurs, over 99% of BVs generated originated from a host-derived angiogenic response stimulated by MSCs. We have shown that this process is dependent on de novo VEGF production likely from implanted MSCs, though we cannot exclude VEGF production from additional, MSC-recruited hostderived cellular sources. Further, autologous MSCs are intrinsically primed to participate and promote a balanced arteriogenic and angiogenic response not otherwise achievable with recombinant growth factors. The aggregate of these observations suggests that a relatively small, clinically practical, implant of MSCs can serve as a beacon for a robust host-derived angiogenic response. Since our experimental observations were made in immunocompetent, nonmyeloablated mice, it is conceivable that MSCs could be exploited therapeutically without need of toxic conditioning regimens as required for classical hematopoietic stem cell transplants. Indeed, we have validated this hypothesis in a rat model of hindlimb ischemia (Al-Khaldi A et al, Annals of Thoracic Surgery, 2002). We propose that ex vivo expanded human MSCs could be implanted in the anatomic compartment requiring therapeutic angiogenesis. The resulting host-derived angiogenic and arteriogenic response may allow for therapeutic revascularization.
